{"disease":{"id":"chaple-disease","name":"CHAPLE disease","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":2,"pipeline_drug_count":0,"trial_count":1},"drugs":{"marketed":[{"drug_id":"pozelimab-bbfg","indication_name":"CD55-deficient PLE (CHAPLE disease)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"VEOPOZ","generic_name":"POZELIMAB-BBFG","company_name":"REGENERON PHARMACEUTICALS","drug_phase":"marketed","molecular_target":"C5","drug_class":"Complement Inhibitor [EPC]","quality_score":50,"revenue":null,"mechanism":"Pozelimab-bbfg blocks C5 cleavage, preventing C5a and C5b formation and inhibiting terminal complement activation."},{"drug_id":"pozelimab","indication_name":"CHAPLE disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Veopoz","generic_name":"POZELIMAB","company_name":"Regeneron","drug_phase":"marketed","molecular_target":"Complement C5","drug_class":"Complement Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Veopoz works by blocking the activity of Complement C5, a protein that contributes to inflammation."},{"drug_id":"pozelimab-bbfg","indication_name":"CHAPLE disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"VEOPOZ","generic_name":"POZELIMAB-BBFG","company_name":"REGENERON PHARMACEUTICALS","drug_phase":"marketed","molecular_target":"C5","drug_class":"Complement Inhibitor [EPC]","quality_score":50,"revenue":null,"mechanism":"Pozelimab-bbfg blocks C5 cleavage, preventing C5a and C5b formation and inhibiting terminal complement activation."}],"pipeline":[],"offLabel":[],"totalMarketed":3,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07142343","title":"A Study to Test the Safety of Pozelimab in Pediatric Participants 1 to 5 Years of Age With a Rare Disease Called CHAPLE (Complement Hyperactivation, Angiopathic Thrombosis, Protein-losing Enteropathy) Disease","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":5,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}